Preclinical and clinical pharmacology of cerivastatin
- 1 August 1998
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 82 (4) , 18J-25J
- https://doi.org/10.1016/s0002-9149(98)00433-0
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatinEuropean Journal of Clinical Pharmacology, 1998
- Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMG-CoA reductase inhibitorJournal of the American College of Cardiology, 1998
- Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitorAtherosclerosis, 1997
- 126 Pharmacokinetics, safety and tolerability of multiple-dose cerivastatin in males and females: a double-blind studyAtherosclerosis, 1997
- 109 Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxinAtherosclerosis, 1997
- 93 Cerivastatin: High enzyme affinity and active metabolites contribute to its high pharmacological activityAtherosclerosis, 1997
- Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary HypercholesterolemiaJournal of Cardiovascular Pharmacology and Therapeutics, 1997
- EFFECT OF THE NEW HMG-CoA REDUCTASE INHIBITOR CERIVASTATIN (BAY W 6228) ON MIGRATION, PROLIFERATION AND CHOLESTEROL SYNTHESIS IN ARTERIAL MYOCYTESPharmacological Research, 1996
- No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and WarfarinThe Journal of Clinical Pharmacology, 1995
- The discovery and development of HMG-CoA reductase inhibitors.Journal of Lipid Research, 1992